Table 1.

Main baseline characteristics of each included trial considered in this meta-analysis.

	Treatment arm	Control arm	Number of patients	Median age	Male (%)	Squamous (%)
CheckMate-227 part 1, 2022 (14)	Nivolumab + ipilimumab	Chemotherapy	583 vs 583	64 vs 64	67.4 vs 66	28 vs 27.8
CheckMate-9LA, 2021 (25)	Nivolumab + ipilimumab + chemotherapy	Chemotherapy	361 vs 358	65 vs 65	70 vs 70	31 vs 31
MYSTIC, 2020 (23)	Durvalumab + tremelimumab	Chemotherapy	372 vs 372	66 vs 64	71.5 vs 67.2	28.8 vs 28.5
	Durvalumab + tremelimumab	Durvalumab (BTMB > 20)	64 vs 77	66 vs 67	73.4 vs 75.3	39.1 vs 37.7
	Durvalumab + tremelimumab	Durvalumab (BTMB < 20)	204 vs 209	65 vs 64	69.6 vs 68.9	27.9 vs 28.2
The Lung-MAP, 2021 (24)	Nivolumab + ipilimumab	Nivolumab	125 vs 127	67 vs 68	66 vs 68	100 vs 100
KEYNOTE-598, 2022 (17)	Pembrolizumab + ipilimumab	Pembrolizumab-placebo	284 vs 284	64 vs 65	71.1 vs 67.3	27.1 vs 28.5
ARCTIC, 2020 (22)	Durvalumab + tremelimumab	Soc	174 vs 118	63 vs 65	66.1 vs 68.6	24.1 vs 23.7
	Durvalumab + tremelimumab	Durvalumab	174 vs 117	63 vs 63	66.1 vs 62.4	24.1 vs 24.8
	Durvalumab + tremelimumab	Tremelimumab	174 vs 60	63 vs 64	66.1 vs 65	24.1 vs 25
CITYSCAPE, 2022 (16)	Tiragolumab + atezolizumab	Atezolizumab-placebo	67 vs 68	68 vs 68	58 vs 71	40 vs 41
NEPTUNE, 2022 (27)	Durvalumab + tremelimumab	Soc (global) a	410 vs 413	NR	72.4 vs 73.8	NR
	Durvalumab + tremelimumab	Soc (China) b	78 vs 82	NR	76.9 vs 69.5	NR
POSEIDON, 2022 (26)	Durvalumab + tremelimumab + Soc	Soc	338 vs 337	63 vs 63	79.6 vs 73.6	NR
	Durvalumab + tremelimumab + Soc	Durvalumab + Soc	338 vs 338	63 vs 64	79.6 vs 74.9	NR

Anti-PD-1 inhibitor: nivolumab and pembrolizumab. Anti-PD-L1 inhibitor: durvalumab and atezolizumab. Anti-CTLA-4 inhibitor: ipilimumab and tremelimumab. Anti-TIGIT inhibitor: tiragolumab.

Soc, standard of care chemotherapy; BTMB, blood tumor mutational burden; NR, not reported.

^aParticipants in global cohort.

^bParticipants in China cohort.